Sunny founded A2-Ai in January of 2023, a venture dedicated to technology-driven clinical pharmacology and pharmacometrics using modern efficiency tools and automation. Previously, she spent time at Sanofi-Aventis, Amgen, and Pfizer. She co-founded her previous business (Ann Arbor Pharmacometrics Group, “A2PG”) in 2007 after Pfizer's departure from its site in Ann Arbor, Michigan. With A2PG, she worked on hundreds of regulatory submissions for clients throughout its highly successful 15 years of PK/PD consulting, until her company was acquired. As a unique leader who is well-versed in both scientific and business aspects of the drug industry, she frequently helps clients proactively find alternative development pathways.
As CTPO of A2-Ai, Devin works with clients to deliver end-to-end solutions that support quantitative decision-making. Devin specializes in bridging the unique characteristics of each client's IT structure with the needs of the scientific team. Some of his focuses for clients include providing strategies to migrate from existing tools to more modern cloud-based workflows, and building prototype tools and dashboards to solve business challenges. Before joining A2-Ai, Devin worked as a principal solutions engineer to help dozens of organizations ranging from the FDA to small biotech and device manufacturers to develop and implement data science solutions.
John brings his extensive experiences in drug development consulting, as well as mentorship for junior scientists, to his role as Chief Pharmacometrics Officer at A2-Ai. His expertise with model-informed drug development allows him to serve clients with a personalized approach and provide creative solutions to their obstacles.
Jack Cook joined A2-Ai in June of 2023 as a Senior Vice President of Clinical Pharmacology. Previously he spent 33 years at Pfizer, where he worked in a multitude of therapeutic areas. He is a fellow of the AAPS, has authored/co-authored over 80 peer-reviewed publications, and also served as an industrial representative for the US Food and Drug Administration's Pharmaceutical Science and Clinical Pharmacology Advisory Committees from 2012 to 2019. His current interests include improving therapy by optimizing drug delivery, and the use of modeling and simulation to make rational decisions in drug development.
Linh Nguyen brings over two decades of profound expertise in pharmaceutical research and development. Specializing in both small and large molecules, Linh has a rich history of leading clinical studies across various therapeutic areas, including oncology, neuropathic pain, and inflammation. Her strategic insights in PK/PD modeling and clinical pharmacology have been pivotal in numerous regulatory filings, leading to successful drug approvals in the U.S. and Europe.
Joseph Ware is a clinical pharmacologist with over 25 years in the pharmaceutical and biotech industries. His expertise spans early to late-stage oncology drug development, ranging from Project Optimus to Project Orbis. Joseph has held key roles at companies such as Pharmacia, Pfizer, Genentech, Acerta/AstraZeneca, Denali, Vincerx, and Seagen.